A Phase 2 interventional study of Magtrace in Ductal Carcinoma in Situ, sponsored by University of Florida. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by University of Florida · Phase 2, Interventional, and Treatment
The standard surgical approach for all patients undergoing mastectomy for the treatment of non-invasive, ductal carcinoma in situ (DCIS) is to perform axillary lymph node staging through use of a traditional sentinel lymph node biopsy (SLNB) procedure where the lymph nodes that drain the breast first are removed at the time of mastectomy. This recommendation for traditional SLNB is due to the risk of finding invasive cancer during surgical evaluation of the mastectomy specimen and the inability to accurately map the lymphatic channels once the breast is removed.
In a study by Herremans et al, the majority of traditional SLNBs were demonstrated to be unnecessary. By using Magtrace, a novel iron based lymphatic mapping agent, a delayed SLNB could eliminate these unnecessary traditional SLNBs.
Magtrace, or superparamagnetic oxide (SPIO), was developed in 2018. Unlike traditional mapping agents of blue dye and technetium that clear the body within 24-48 hours, Magtrace remains in the lymph nodes for at least 4 weeks. Magtrace's ability to remain in the lymph node allows accurate mapping of the lymph nodes at the time of the mastectomy with the ability to return to the operating room for a delayed sentinel lymph node biopsy if invasive cancer is found on final pathology.
This study will investigate whether the use of Magtrace will successfully allow patients with DCIS undergoing mastectomy to avoid undergoing SLNB.
205 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 46 are open to participants now.
This study's planned enrollment of 30 is below the median of 69 across 155 interventional studies indexed under Carcinoma, Intraductal, Noninfiltrating.
Browse Carcinoma, Intraductal, Noninfiltrating studies →University of Florida is the lead sponsor of 1,254 studies on the registry; 201 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 136 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with a core needle biopsy diagnosis consistent with ductal carcinoma in-situ (DCIS), Stage 0 breast cancer, who are planning to undergo a mastectomy.
o The mastectomy can be with or without reconstruction and with or without contralateral prophylactic mastectomy.
Exclusion Criteria:
Drug: Magtrace
Participants will receive a single injection of Magtrace into the breast during their mastectomy.
Percentage of patients with DCIS who do not undergo sentinel lymph node biopsy
Determine the percentage of patients with DCIS who do not undergo sentinel lymph node biopsy.
Time frame: 24 months post-mastectomy
Percentage of patients that are found to have invasive disease at time of mastectomy
Determine the Percentage of patients that are found to have invasive disease at time of mastectomy.
Time frame: At the time of mastectomy
Rate of return to operating room for delayed sentinel lymph node biopsy
Determine the number of patients who return to the operating room for delayed sentinel lymph node biopsy.
Time frame: 24 months post-mastectomy
Patient-reported outcomes measures
Compare the scores obtained to the historical control for each of the following scales of the Breast-Q questionnaire: psychosocial well-being, sexual well-being, cancer worry, fatigue, and impact on work.
Time frame: 24 months post-mastectomy
This study is suspended, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Intraductal, Noninfiltrating→
University of Florida